Clearstead Advisors’s NovoCure NVCR Stock Holding History

Clearstead Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.52K	Buy	158 +92	+139%	+$1.54K	﹤0.01%	2413
2026 Q2	$1K	Buy	+66	New	+$999	﹤0.01%	2690
2026 Q1	–	Sell	-13	Closed	-$169	–	2662
2025 Q4	$169	Sell	13 -274	-95%	-$3.52K	﹤0.01%	2443
2025 Q3	$3.71K	Buy	+287	New	+$3.84K	﹤0.01%	2268
2023 Q3	–	Sell	-25	Closed	-$1.04K	–	1505
2023 Q2	$1.04K	Hold	25	–	–	﹤0.01%	1244
2023 Q1	$1.5K	Hold	25	–	–	﹤0.01%	1183
2022 Q4	$1.83K	Hold	25	–	–	﹤0.01%	1106
2022 Q3	$2K	Hold	25	–	–	﹤0.01%	1087
2022 Q2	$2K	Hold	25	–	–	﹤0.01%	1118
2022 Q1	$2K	Buy	25 +5	+25%	+$368	﹤0.01%	1219
2021 Q4	$2K	Hold	20	–	–	﹤0.01%	1123
2021 Q3	$2K	Hold	20	–	–	﹤0.01%	1140
2021 Q2	$4K	Hold	20	–	–	﹤0.01%	924
2021 Q1	$3K	Buy	20 +10	+100%	+$1.58K	﹤0.01%	925
2020 Q4	$2K	Hold	10	–	–	﹤0.01%	894
2020 Q3	$1K	Buy	+10	New	+$800	﹤0.01%	849

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Quantinno Capital Management New York $106B AUM 29.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Clearstead Advisors's NVCR Position: Q3 2026 in Review

Clearstead Advisors increased its NovoCure (NVCR) stake by 139% in Q3 2026, buying an estimated $1.54K and bringing the position to 158 shares worth $2.52K. The position accounts for ﹤0.01% of the portfolio, ranked #2413.

Clearstead Advisors first reported a position in NVCR in Q3 2020 and has held it in 16 quarters since. The position peaked at $4K in Q2 2021. 183 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

Clearstead Advisors held 158 shares of NovoCure worth $2.52K as of Q3 2026.
Clearstead Advisors bought 92 NovoCure shares in Q3 2026, an estimated $1.54K.
NovoCure made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #2413 holding.
Clearstead Advisors first reported a position in NovoCure in Q3 2020 and has held it in 16 quarters since.
Clearstead Advisors's NovoCure position peaked at $4K in Q2 2021.
183 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.